Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease DOI Creative Commons
Mykhailo Buchynskyi, Iryna Kamyshna, Iryna Halabitska

et al.

Frontiers in Microbiology, Journal Year: 2025, Volume and Issue: 16

Published: April 25, 2025

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a complex metabolic disorder characterized by hepatic lipid accumulation and subsequent inflammation. This condition closely linked to syndrome obesity, with its prevalence rising due sedentary lifestyles high-calorie diets. The pathogenesis of MAFLD involves multiple factors, including insulin resistance, lipotoxicity, oxidative stress, inflammatory responses. gut microbiota plays crucial role in development, dysbiosis contributing inflammation through various mechanisms, such as enhanced intestinal permeability the translocation bacterial products like lipopolysaccharide (LPS). Microbial metabolites, short-chain acids (SCFAs) bile acids, influence function immune responses, potential implications for progression. Specific microbiome signatures have been identified patients, offering diagnostic therapeutic targets. Moreover, gut-derived toxins, endotoxins, lipopolysaccharides, trimethylamine-N-oxide significantly damage inflammation, highlighting interplay between health. review comprehensively examines MAFLD, focusing on underlying pathogenic biomarkers, emerging microbiome-targeted strategies management.

Language: Английский

Chicken meat hydrolysate improves acetaminophen-induced liver injury by alleviating oxidative stress via modulation in Keap1/Nrf2/HO-1 signaling in BALB/c mice DOI Creative Commons
Vipul Wayal,

Zhuo-En Tsai,

Yu‐Hsuan Lin

et al.

Journal of Agriculture and Food Research, Journal Year: 2025, Volume and Issue: unknown, P. 101863 - 101863

Published: March 1, 2025

Language: Английский

Citations

0
Exploring food-derived bioactive peptides: efficacy, mechanisms, and clinical implications in ferroptosis regulation DOI
Chenzhe Gao, Long Zhang,

Jiahui Ma

et al.

Trends in Food Science & Technology, Journal Year: 2025, Volume and Issue: unknown, P. 105014 - 105014

Published: April 1, 2025

Language: Английский

Citations

0
Luteolin Relieves Metabolic Dysfunction-Associated Fatty Liver Disease Caused by a High-Fat Diet in Rats Through Modulating the AdipoR1/AMPK/PPARγ Signaling Pathway DOI Open Access

Pongsakorn Taweesap,

Prapassorn Potue, Juthamas Khamseekaew

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(8), P. 3804 - 3804

Published: April 17, 2025

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a significant global public health issue. Luteolin possesses several beneficial biological properties, including antioxidation and anti-inflammation. This study investigated luteolin’s effect potential mechanisms on MAFLD in high-fat diet (HFD)-fed rats. Rats were administered an HFD supplemented with fructose for 12 weeks to induce MAFLD. After that, the HFD-fed rats given either luteolin (50 or 100 mg/kg/day) metformin (100 4 weeks. improved metabolic parameters induced by HFD, since it decreased body weight, blood pressure, fasting glucose, serum insulin, free acids, cholesterol, triglyceride levels (p < 0.05). reduced hepatic injury inflammatory markers Additionally, treated showed malondialdehyde raised catalase activity plasma attenuated steatosis compared untreated also increased adiponectin accompanied upregulation of receptor 1 (AdipoR1), AMP-activated protein kinase (AMPK), peroxisome proliferator-activated γ (PPAR-γ) expression These findings revealed that ameliorated HFD-induced rats, possibly reducing alterations oxidative stress restoring AdipoR1, AMPK, PPARγ

Language: Английский

Citations

0
Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease DOI Creative Commons
Mykhailo Buchynskyi, Iryna Kamyshna, Iryna Halabitska

et al.

Frontiers in Microbiology, Journal Year: 2025, Volume and Issue: 16

Published: April 25, 2025

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a complex metabolic disorder characterized by hepatic lipid accumulation and subsequent inflammation. This condition closely linked to syndrome obesity, with its prevalence rising due sedentary lifestyles high-calorie diets. The pathogenesis of MAFLD involves multiple factors, including insulin resistance, lipotoxicity, oxidative stress, inflammatory responses. gut microbiota plays crucial role in development, dysbiosis contributing inflammation through various mechanisms, such as enhanced intestinal permeability the translocation bacterial products like lipopolysaccharide (LPS). Microbial metabolites, short-chain acids (SCFAs) bile acids, influence function immune responses, potential implications for progression. Specific microbiome signatures have been identified patients, offering diagnostic therapeutic targets. Moreover, gut-derived toxins, endotoxins, lipopolysaccharides, trimethylamine-N-oxide significantly damage inflammation, highlighting interplay between health. review comprehensively examines MAFLD, focusing on underlying pathogenic biomarkers, emerging microbiome-targeted strategies management.

Language: Английский

Citations

0